TG Therapeutics, Inc. $TGTX Shares Acquired by Russell Investments Group Ltd.

Key Points

• Russell Investments Group Ltd. increased its holdings in TG Therapeutics by 338.6% during Q1, owning over 152,000 shares valued at approximately $6 million.
• Goldman Sachs upgraded TG Therapeutics to a "hold" rating with a price target of $37.00, while the stock currently has an average rating of "Moderate Buy" and a target price of $46.25.
• TG Therapeutics reported a net loss with $0.17 EPS for the last quarter, missing the consensus estimate of $0.32, and had revenues of $141.15 million.

Russell Investments Group Ltd. lifted its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 338.6% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 152,214 shares of the biopharmaceutical company's stock after acquiring an additional 117,508 shares during the period. Russell Investments Group Ltd. owned approximately 0.10% of TG Therapeutics worth $6,002,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Allspring Global Investments Holdings LLC grew its stake in shares of TG Therapeutics by 54.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 23,775 shares of the biopharmaceutical company's stock worth $898,000 after acquiring an additional 8,338 shares during the last quarter. New York State Teachers Retirement System grew its stake in shares of TG Therapeutics by 175.0% during the first quarter. New York State Teachers Retirement System now owns 120,364 shares of the biopharmaceutical company's stock worth $4,746,000 after acquiring an additional 76,600 shares during the last quarter. Crossmark Global Holdings Inc. purchased a new stake in shares of TG Therapeutics during the first quarter worth about $226,000. GAMMA Investing LLC grew its stake in shares of TG Therapeutics by 77.7% during the first quarter. GAMMA Investing LLC now owns 4,543 shares of the biopharmaceutical company's stock worth $179,000 after acquiring an additional 1,986 shares during the last quarter. Finally, Braun Stacey Associates Inc. grew its stake in shares of TG Therapeutics by 13.5% during the first quarter. Braun Stacey Associates Inc. now owns 502,650 shares of the biopharmaceutical company's stock worth $19,819,000 after acquiring an additional 59,845 shares during the last quarter. Hedge funds and other institutional investors own 58.58% of the company's stock.

Insider Transactions at TG Therapeutics

In other TG Therapeutics news, Director Yann Echelard sold 10,000 shares of the business's stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $36.94, for a total value of $369,400.00. Following the completion of the transaction, the director directly owned 228,816 shares of the company's stock, valued at approximately $8,452,463.04. The trade was a 4.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 10.64% of the company's stock.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group upgraded TG Therapeutics to a "hold" rating and set a $37.00 price target on the stock in a research note on Thursday, July 10th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $46.25.

TG Therapeutics Stock Performance

NASDAQ:TGTX traded down $0.25 during trading hours on Tuesday, reaching $28.28. The company had a trading volume of 1,551,290 shares, compared to its average volume of 2,905,861. TG Therapeutics, Inc. has a 1-year low of $21.11 and a 1-year high of $46.48. The firm has a market cap of $4.49 billion, a PE ratio of 76.43 and a beta of 1.95. The business's 50 day moving average price is $33.82 and its 200-day moving average price is $35.64. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.86 and a quick ratio of 2.96.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The company had revenue of $141.15 million during the quarter, compared to analyst estimates of $147.76 million. During the same period in the previous year, the firm posted $0.04 earnings per share. The company's revenue was up 92.1% compared to the same quarter last year. TG Therapeutics has set its FY 2025 guidance at EPS. Research analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.